Categories for Featured

New Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Shows Promise for Treatment of Bronchiectasis

October 21, 2018 3:18 pm Published by

SYRACUSE, NY, January 12, 2017 – Monaghan Medical Corporation (MMC) today announced that the findings of a study published in the most recent issue of Academic Radiology shows that patients with non-cystic fibrosis (CF) bronchiectasis responded favorably to airway maintenance therapy using the AEROBIKA® device. This latest study adds to the growing base of evidence that demonstrates Monaghan’s drug-free AEROBIKA® device is effective for lung health maintenance. In this latest Read Post >>

Monaghan’s drug-free Aerobika® device helps reduce the real-world impact of exacerbations in chronic obstructive pulmonary disease

October 22, 2018 3:11 pm Published by

SYRACUSE, NY, 21 February, 2017 – Monaghan Medical Corporation (MMC) today announced the publication of a study in Pulmonary Therapy showing treatment with the AEROBIKA® device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day period following hospitalization or emergency room visits.1 The study also showed that per-patient cost of exacerbations was significantly lower in the group using the AEROBIKA® device.  This study provides the first Read Post >>

Significant reductions in costly pulmonary complications with use of drug-free device

October 23, 2018 3:16 pm Published by

Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system.  A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA® oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1 The retrospective database analysis including 288 patients undergoing cardiac, thoracic or upper abdominal surgery suggests that use of the AEROBIKA® OPEP device in addition to standard of care (incentive spirometry, Read Post >>